Skip to content

King Pharmaceuticals KG Q3 2025 earnings

Reported November 5, 2025 · Before market open

Next report

Aug 7, 2026 (In 3 weeks)
Revenue estimate$338.6M

Financials

Q3 2025

Income statement

See full
Revenue$17.4M+2,220%
Net income-$5.1M-1,078%
EPS (diluted)-$0.65-306%

Balance sheet

See full
Cash & equivalents$40.5M+800%
Total debt$176.2M
Total equity$143.8M+3,106%
Total assets$1.1B

Cash flow

See full
Operating cash flow-$9.7M-1,895%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$211.43M
Enterprise value$347.1M
P/S8.4×

Returns & leverage

See full
Debt / equity1.2×

Versus estimates

Ask the moment King Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did King Pharmaceuticals report Q3 2025 earnings?
King Pharmaceuticals (KG) reported Q3 2025 earnings on November 5, 2025 before market open.
What were King Pharmaceuticals's Q3 2025 revenue and EPS?
King Pharmaceuticals reported revenue of $20.3M and diluted EPS of $-1.95 for Q3 2025.
Where can I find King Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-049605) and the 10-Q periodic report (0001628280-25-049606) directly on SEC EDGAR. The filing index links above go to sec.gov.